Podcast
Questions and Answers
What is the recommended action if a patient receiving trastuzumab therapy experiences a decrease in LVEF?
What is the recommended action if a patient receiving trastuzumab therapy experiences a decrease in LVEF?
- Increase trastuzumab dosage
- Continue trastuzumab therapy
- Withhold trastuzumab therapy and reassess LVEF after four weeks (correct)
- Discontinue trastuzumab therapy immediately
Which of the following factors increases the risk of trastuzumab cardiotoxicity?
Which of the following factors increases the risk of trastuzumab cardiotoxicity?
- Male gender
- Underweight
- Previous or concurrent use of taxanes (correct)
- Young age
What is the recommended treatment for trastuzumab-induced heart failure?
What is the recommended treatment for trastuzumab-induced heart failure?
- No treatment is necessary
- Standard heart failure medication (correct)
- Antibiotics
- Surgery
Flashcards are hidden until you start studying
Study Notes
- Trastuzumab cardiotoxicity can cause a decrease in LVEF and clinical heart failure.
- Symptoms of heart failure have been reported in 3-7% of patients receiving trastuzumab.
- Age, previous or concurrent anthracycline use, and obesity are risk factors for trastuzumab cardiotoxicity.
- Cardiac function monitoring is recommended for patients receiving anthracyclines and trastuzumab.
- Patients should be counseled on reducing cardiovascular risk through lifestyle changes.
- Standard heart failure medication is recommended for trastuzumab-induced heart failure.
- Trastuzumab therapy should be withheld and LVEF reassessed after four weeks.
- If LVEF remains low, trastuzumab should be discontinued.
- Prophylactic use of beta blockers or ACEi/ARB may be beneficial for high-risk patients.
- Cardiac biopsy specimens do not show significant myocyte destruction.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.